Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kozlowski, O. Kowalczuk, G. Lapuc, A. Sulewska, W. Laudanski, M. Garbowicz, W. Niklinska, P. Dziegielewski, L. Chyczewski, J. Niklinski, J. Laudanski (Bialystok, Poland). Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report. Eur Respir J 2008; 32: Suppl. 52, 1405

Member's Comments

No comment yet.

Related content which might interest you: Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009 Vascular endothelial growth factor (VEGF) expression in non small cell lung cancer and its association with histopathologic type, stage, lymphnode involvement, recurrence and distant metastasis Source: Eur Respir J 2003; 22: Suppl. 45, 393s Year: 2003 Vascular endothelial growth factor (VEGF) in serum and exhaled breath condensate (EBC) of subjects with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 205s Year: 2007 The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018 Vascular endothelial growth factor (VEGF) in serum and exhaled breath condensate (EBC) as a potential biomarker for early detection of non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012